

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Error
1	BRS	L1	77	gelatin near human	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 13:21			0
2	BRS	L2	7	1 same fragment	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 13:24			0
3	BRS	L3	0	1 same proteoly\$5	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 13:25			0
4	BRS	L4	3	1 same hydroly\$4	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 13:25			0

FILE 'HOME' ENTERED AT 13:30:25 ON 20 MAR 2003

=> file medline caplus biosis embase scisearch agricola

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 13:30:50 ON 20 MAR 2003

FILE 'CAPLUS' ENTERED AT 13:30:50 ON 20 MAR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:30:50 ON 20 MAR 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 13:30:50 ON 20 MAR 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:30:50 ON 20 MAR 2003

COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 13:30:50 ON 20 MAR 2003

=> s human gelatin

L1 70 HUMAN GELATIN

=> s l1 (p) (fragment or proteoly?)

L2 4 L1 (P) (FRAGMENT OR PROTEOLY?)

=> duplicate remove l2

ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove l2

'REMOVE L14' IS NOT VALID HERE

Enter "REMOVE" to identify and remove duplicate answers.

Enter "IDENTIFY" to identify duplicate answers in the answer set.

Enter "ONLY" to identify and create an answer set containing only duplicate records.

ENTER REMOVE, IDENTIFY, ONLY, OR (?):end

=> duplicate remove l2

PROCESSING COMPLETED FOR L2

L3 4 DUPLICATE REMOVE L2 (0 DUPLICATES REMOVED)

=> d l3 1-4 ibib abs

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:360174 CAPLUS

DOCUMENT NUMBER: 134:365701

TITLE: Recombinant gelatins derived from type I collagen
.alpha.1 chain, and pharmaceutical applications in
vaccines thereof

INVENTOR(S): Chang, Robert C.; Kivirikko, Kari I.; Neff, Thomas B.;
Olsen, David R.; Polarek, James W.

PATENT ASSIGNEE(S): Fibrogen, Inc., USA

SOURCE: PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001034801	A2	20010517	WO 2000-US30843	20001110
WO 2001034801	A3	20020131		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, ST, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BG, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1232262 A2 20020821 EP 2000-978469 20001110

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

US 1999-165114P P 19991112
US 2000-204437P P 20000515
WO 2000-US30843 W 20001110

AB The present invention relates to vaccines comprising recombinant gelatin, to methods of producing and using such vaccines, and to vaccination kits. The present invention relates to recombinant gelatins and compns. thereof, and methods of producing and using the same. ***Human***

gelatins with discrete ***fragments*** of the .alpha.1(I) chain of human type I collagen is produced using a yeast multi-gene recombinant expression system. Specific ***fragments*** of cDNA for .alpha.1(I) chain from human type I collagen is cloned for the expression in Pichia pastoris which is also transformed with genes for the .alpha. or .beta. subunit of human prolyl 4-hydroxylase, which is used to improve the stability of the recombinant gelatins. Well-defined, highly homogenous gelatin ***fragments*** ranging in size from 6-65 kDa are produced, which can support cell attachment activity, have lower level endotoxin contamination, and are ***proteolytically*** more stable. The peptide profile of thermal, acid, and enzymic hydrolysis anal., and antigenicity of these recombinant gelatins are studied. This presents unsurpassed flexibility in terms of the size and biophys. properties of the gelatin that can be used for pharmaceutical or industrial applications.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:360037 CAPLUS

DOCUMENT NUMBER: 134:362228

TITLE: Recombinant gelatins derived from type I collagen .alpha.1 chain, and pharmaceutical and industrial applications thereof

INVENTOR(S): Chang, Robert C.; Kivirikko, Kari I.; Neff, Thomas B.; Olsen, David R.; Polarek, James W.

PATENT ASSIGNEE(S): Fibrogen, Inc., USA

SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001034646	A2	20010517	WO 2000-US30791	20001110
WO 2001034646	A3	20011206		
WO 2001034646	C2	20021121		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1232181 A2 20020821 EP 2000-978455 20001110

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

US 1999-165114P P 19991112
US 2000-204437P P 20000515
WO 2000-US30791 W 20001110

AB The present invention relates to recombinant gelatins and compns. thereof, and methods of producing and using the same. ***Human***

gelatins with discrete ***fragments*** of the .alpha.1(I) chain of human type I collagen is produced using a yeast multi-gene recombinant expression system. Specific ***fragments*** of cDNA for .alpha.1(I) chain from human type I collagen is cloned for the expression

in *Pichia pastoris* which is also transformed with genes for the alpha. or .beta. subunit of human prolyl-4-hydroxylase, which is used to improve the stability of the recombinant gelatins. Well-defined, highly homogenous gelatin ***fragments*** ranging in size from 6-65 kDa are produced, which can support cell attachment activity, have lower level endotoxin contamination, and are ***proteolytically*** more stable. The peptide profile of thermal, acid, and enzymic hydrolysis anal., and antigenicity of these recombinant gelatins are studied. This presents unsurpassed flexibility in terms of the size and biophys. properties of the gelatin that can be used for pharmaceutical or industrial applications.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1987:513072 CAPLUS

DOCUMENT NUMBER: 107:113072

TITLE: Gelatin-binding fragments of fibronectin as possible inhibitors of connective tissue cell proliferation

AUTHOR(S): Abakumova, O. Yu.; Kutsenko, N. G.; Mitina, V. Kh.; Panasyuk, A. F.; Orekhovich, V. N.

CORPORATE SOURCE: Inst. Biol. Med. Khim., Moscow, USSR

SOURCE: Doklady Akademii Nauk SSSR (1987), 294(4), 984-8 [Biochem.]

CODEN: DANKAS; ISSN: 0002-3264

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB A DNA synthesis inhibitor was detected in cultured human skin fibroblasts. This inhibitor was found to be a fragment of fibronectin, which was released by proteolytic cleavage of fibronectin. The inhibitor had high affinity for gelatin. The isolation, characterization, and possible functions of the inhibitor are considered.

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1985:537390 CAPLUS

DOCUMENT NUMBER: 103:137390

TITLE: Interaction of gelatin with a fluorescein-labeled 42-kDa chymotryptic fragment of fibronectin

AUTHOR(S): Forastieri, Hilda; Ingham, Kenneth C.

CORPORATE SOURCE: Plasma Plasma Derivat. Lab, Am. Red Cross, Bethesda, MD, 20814, USA

SOURCE: Journal of Biological Chemistry (1985), 260(19), 10546-50

CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A 42-kilodalton gelatin-binding fragment of human plasma fibronectin was labeled with fluorescein and its fluid-phase interaction with gelatin was investigated. At 25.degree. in 0.1M Tris, 0.15M NaCl, pH 7.3, a dissocn. const. (Kd) of 0.6 .mu.M was obtained from the dependence of fluorescence polarization on gelatin concn. An identical value was obtained for the unlabeled fragment by competition. Binding was unaffected by higher concns. of NaCl (.ltoreq.1M), but increased as much as 20-fold at low ionic strength. The dependence of Kd on temp. revealed that dissocn. of the complex is accompanied by an increase in entropy. Thus, the interaction is not dominated by either hydrophobic or electrostatic forces; an important role for H-bonding is proposed.

=> d his

(FILE 'HOME' ENTERED AT 13:30:25 ON 20 MAR 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 13:30:50 ON 20 MAR 2003

L1 70 S HUMAN GELATIN

L2 4 S L1 (P) (FRAGMENT OR PROTEOLY?)

L3 4 DUPLICATE REMOVE L2 (0 DUPLICATES REMOVED)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.29

22.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY
-2.60

SESSION
-2

STN INTERNATIONAL LOGOFF AT 13:33:32 ON 20 MAR 2003

=> d his

(FILE 'HOME' ENTERED AT 12:57:53 ON 19 MAR 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'
ENTERED AT

12:58:13 ON 19 MAR 2003

L1 70 S HUMAN GELATIN
L2 102 S HUMAN (A) GELATIN
L3 102 S L1 OR L2
L4 124357 S KDA (P) 3
L5 11 S L3 (P) KDA
L6 4 DUPLICATE REMOVE L5 (7 DUPLICATES REMOVED)
L7 59 S BLOOM STRENGTH
L8 0 S L3 (P) L7
L9 108768 S GELATIN
L10 70 S L9 (P) HYDROXYLAT?
L11 0 S L10 (P) PERCENT?
L12 0 S L3 (P) NON-HYDROXYLAT?
L13 53 S GELATIN POLYPEPTIDE
L14 0 S L13 (P) (MIXTURE OR HOMOGENEOUS)
L15 7 S L3 (P) (HETEROGENEOUS OR MIXTURE)
L16 3 DUPLICATE REMOVE L15 (4 DUPLICATES REMOVED)
L17 16 S L3 (P) COLLAGEN
L18 8 DUPLICATE REMOVE L17 (8 DUPLICATES REMOVED)
L19 8 S L18 NOT L16 OR L6
L20 5 S L3 (P) COMPOSITION
L21 4 DUPLICATE REMOVE L20 (1 DUPLICATE REMOVED)
L22 127071 S ENDOTOXIN
L23 174 S L9 (P) L22
L24 12 S L23 (P) FREE
L25 7 DUPLICATE REMOVE L24 (5 DUPLICATES REMOVED)

=> log y